Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF-κB in mice fed a high-fat diet

Molecular Medicine Reports

Volumn 14, Issue 2, 2016, Pages 1323-1331

  Liu, Zhenxiong ^a   Dou, Weijia ^a   Ni, Zhen ^b   Wen, Qinsheng ^a   Zhang, Rong ^c   Qin, Ming ^a   Wang, Xuxia ^a   Tang, Hua ^a   Cao, Ying ^a   Wang, Jingjie ^a   Zhao, Shuguang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c YAN'AN UNIVERSITY   (China)

Author keywords

Insulin resistance; Non alcoholic fatty liver disease; Nuclear erythroid 2 related factor 2; Nuclear factor B; Oxidative stress

Indexed keywords

GLUCOSE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; GLUCOSE BLOOD LEVEL; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEPATIC INSULIN RESISTANCE; HISTOPATHOLOGY; INSULIN RESISTANCE; LIPID DIET; LIPID PEROXIDATION; LIPID STORAGE; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; DEFICIENCY; DISEASE MODEL; GENE DELETION; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE DELETION; GLUTATHIONE; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84978412213     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5393     Document Type: Article

References (37)

1. Musso G, Gambino R, Cassader M and Pagano G: Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617-649, 2011.
2. Preiss D and Sattar N: Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 115: 141-150, 2008.
3. Day CP and James OF: Steatohepatitis: A tale of two 'hits'? Gastroenterology 114: 842-845, 1998.
4. Musso G, Gambino R and Cassader M: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26, 2009.
5. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ and Shulman GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353, 2004.
6. Bugianesi E, Mccullough AJ and Marchesini G: Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 42: 987-1000, 2005.
7. Wellen KE and Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119, 2005.
8. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H and Zick Y: A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272: 29911-29918, 1997.
9. Houstis N, Rosen ED and Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440: 944-948, 2006.
10. Videla LA, Rodrigo R, Araya J and Poniachik J: Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 12: 555-558, 2006.
11. Evans JL, Maddux BA and Goldfine ID: The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 7: 1040-1052, 2005.
12. Zhang DD and Hannink M: Distinct cysteine in Keap1 are required for Keap1-dependent ubiquitination on Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23: 8137-8151, 2003.
13. Bataille AM and Manautou JE: Nrf2: A potential target for new therapeutics in liver disease. Clin Pharmacol Ther 92: 340-348, 2012.
14. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
15. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML and Hayes JD: Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48: 357-371, 2010.
16. Luley C, Ronquist G, Reuter W, Paal V, Gottschling HD, Westphal S, King GL, Bakker SJ, Heine RJ and Hattemer A: Point-of-care testing of triglycerides: Evaluation of the Accutrend triglycerides system. Clin Chem 46: 287-291, 2000.
17. Amaral ME, Oliveira HC, Carneiro EM, Delghingaro-Augusto V, Vieira EC, Berti JA and Boschero AC: Plasma glucose regulation and insulin secretion in hypertriglyceridemic mice. Horm Metab Res 34: 21-26, 2002.
18. Angel MF, Ramasastry SS, Swartz WM, Narayanan K, Kuhns DB, Basford RE and Futrell JW: The critical relationship between free radicals and degrees of ischemia: Evidence for tissue intolerance of marginal perfusion. Plast Reconstr Surg 81: 233-239, 1988.
19. Zhong D, Zhang Y, Zeng YJ, Gao M, Wu GZ, Hu CJ, Huang G and He FT: MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXR?. Lipids Health Dis 12: 32, 2013.
20. He L, Wang H, Jin H, Guo C, Xie H, Yan K, Li X, Shen Q, Qiao T, Chen G, et al: CIAPIN1 inhibits the growth and proliferation of clear cell renal cell carcinoma. Cancer Lett 276: 88-94, 2009.
21. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J and Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11: 191-198, 2005.
22. Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, Miyagi I and Enjoji M: Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 16: 631-635, 2005.
23. Mantena SK, King AL, Andringa KK, Eccleston HB and Bailey SM: Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol-and obesity-induced fatty liver diseases. Free Radic Biol Med 44: 1259-1272, 2008.
24. Kobayashi M and Yamamoto M: Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46: 113-140, 2006.
25. Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP and Rabb H: Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 76: 277-285, 2009.
26. Chan K, Lu R, Chang JC and Kan YW: NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci USA 93: 13943-13948, 1996.
27. Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, Tokushige K, Hashimoto E, Utsunomiya H, Takahashi H, Ishii T, et al: Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J Gastroenterol 48: 620-632, 2013.
28. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, Taguchi K, Yanagawa T, Nakahara A, Hyodo I, et al: Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 298: G283-G294, 2010.
29. Marchesini G and Forlani G: NASH: From liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35: 497-499, 2002.
30. Hebbard L and George J: Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 8: 35-44, 2011.
31. Biddinger SB and Kahn CR: From mice to men: Insights into the insulin resistance syndromes. Annu Rev Physiol 68: 123-158, 2006.
32. Tilg H and Moschen AR: Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19: 371-379, 2008.
33. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N and Geerts A: Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol 47: 142-156, 2007.
34. Barnes PJ and Karin M: Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997.
35. Baker RG, Hayden MS and Ghosh S: NF-B, inflammation, and metabolic disease. Cell Metab 13: 11-22, 2011.
36. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J and Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190, 2005.
37. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.